J&J’s Carvykti Claims Broadest CAR-T Label In Multiple Myeloma

 
• By Bridget Silverman
  
multiple myeloma
Carvykti can be used in an earlier line of therapy than Bristol Myers Squibb/2seventy bio’s rival CAR-T Abecma. • Source: Shutterstock
Pink Sheet Podcast

Learn what's happening at the US FDA. On the go.

Derrick Gingery and the team bring you a weekly "Drug Fix".

SpotifyApple PodcastsWebsite

More from Approvals

More from Product Reviews